Pneumologie 2025; 79(S 01): S108-S109
DOI: 10.1055/s-0045-1804783
Abstracts
D2 – Grundlagen- und translationale Lungenforschung

TORREY Phase 2 Study of Seralutinib in Pulmonary Arterial Hypertension (PAH): Circulating Biomarkers of Proliferation, Inflammation and Fibrosis Improve with Treatment

H Ghofrani
1   Universitätsklinikum Gießen und Marburg Gmbh; Standort Gießen; Med. Klinik Ii/V
,
R Osterhout
2   Gossamer Bio, Inc.
,
R Benza
3   Icahn School of Medicine at Mount Sinai, Mount Sinai Hospital
,
R Channick
4   Massachusetts General Hospital, Harvard Medical School; Ucla Medical Center
,
K Chin
5   Ut Southwestern Medical Center; Ut Southwestern Medical Center
,
R Frantz
6   Mayo Clinic
,
A Hemnes
7   Vanderbilt University, Vanderbilt University Medical Center
,
L Howard
8   Hammersmith Hospital Imperial College Healthcare NHS Trust; Hammersmith Hospital
,
V McLaughlin
9   University of Michigan Health System Division of Cardiovascular Medicine; University of Michigan
,
O Sitbon
10   Hôpital Bicêtre (Ap-Hp), Université Paris-Saclay
,
J Vachiéry
11   Université Libre de Bruxelles, Hub – Hôpital Erasme
,
R Roscigno
2   Gossamer Bio, Inc.
,
D Mottola
2   Gossamer Bio, Inc.
,
R Sitapara
2   Gossamer Bio, Inc.
,
R Aranda
2   Gossamer Bio, Inc.
,
L Zisman
2   Gossamer Bio, Inc.
,
J Bruey
2   Gossamer Bio, Inc.
,
R Zamanian
12   Stanford University School of Medicine, Stanford Medicine
› Author Affiliations
› Further Information
Also available ateRef
 
 

    Seralutinib is a novel, inhaled tyrosine kinase inhibitor targeting PDGFRα/ß, CSF1R, and c-KIT pathways that drive pulmonary arterial vascular remodeling in PAH. In the phase 2 TORREY study of seralutinib in patients with WHO Group 1 PH (Functional Class II/III on stable PAH-specific background therapy; NCT04456998), seralutinib met its primary endpoint by demonstrating a significant reduction in pulmonary vascular resistance at Week 24 (-14.3%; p=0.0310). In an exploratory analysis, circulating proteins were measured to characterize the impact of seralutinib on biomarkers and their correlation with hemodynamic response.

    Plasma samples were collected at baseline and Week 24. Proteomics data were generated using the Olink Explore 3072 assay. Robust regression models were applied to identify treatment-associated protein changes.

    Paired proteomics data were available for 70 patients (31 seralutinib, 39 placebo). 223 proteins were associated with seralutinib treatment (p<0.05), spanning functions relevant to PAH disease biology and the seralutinib mechanism of action, including proliferation, inflammation, fibrosis, extracellular matrix and vascular remodeling. For example, NT-proBNP, Endoglin, COL1A1, FLT1 and ANGPT2 were downregulated by seralutinib, whereas IL10 was upregulated. Enriched pathways were consistent with results seen in preclinical models. Many of the pharmacodynamic effects were correlated with cardiopulmonary hemodynamics and measures of right heart function and were directionally consistent with improvement in disease activity.

    The observed protein biomarker changes suggest that seralutinib has a significant impact on inflammatory, proliferative and fibrotic pathways, concordant with clinical improvement in patients with PAH. A phase 3 study of seralutinib in PAH is enrolling (PROSERA, NCT05934526).


     

    Publication History

    Article published online:
    18 March 2025

    © 2025. Thieme. All rights reserved.

    Georg Thieme Verlag KG
    Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany